Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with <i>BRCA1/2</i> - and Non– <i>BRCA1/2</i> -Mutant Cancers
Timothy A. Yap(The University of Texas MD Anderson Cancer Center), Johann S. de Bono(Royal Marsden NHS Foundation Trust), Mona Parmar(Institute of Cancer Research), Bristi Basu(University of Cambridge), Alison Turner(Institute of Cancer Research), Joline S.J. Lim(National University Cancer Institute, Singapore), Udai Banerji(Institute of Cancer Research), Heidrun Gevensleben(University Hospital Bonn), Shaun Decordova(Institute of Cancer Research), Ruth Plummer(National Health Service), Laura Finneran(Institute of Cancer Research), Nina Tunariu(Leicester Royal Infirmary), Florence I. Raynaud(Institute of Cancer Research), Ruth Ruddle(Institute of Cancer Research), Emma Hall(Institute of Cancer Research), Nicholas C. Turner(Institute of Cancer Research), Yvette Drew(Newcastle University), Susana Miranda(Royal Marsden NHS Foundation Trust), Ruth Matthews(Institute of Cancer Research), Juanita Lopez(Institute of Cancer Research), Rowan Miller(Queen Mary University of London), Ruth Riisnaes(Institute of Cancer Research), Paul Rugman(AstraZeneca (United Kingdom)), Desamparados Roda(Institute of Cancer Research), Justin P.O. Lindemann(University Hospital Ostrava), Daniel Nava Rodrigues(Institute of Cancer Research), Suzanne Carreira(Institute of Cancer Research), Andrew Foxley(AstraZeneca (United Kingdom)), Stephen J. Pettitt(Gene Therapy Laboratory), Christopher J. Lord(Institute of Cancer Research), Rebecca Kristeleit(Guy's and St Thomas' NHS Foundation Trust), Sarah Ward(Institute of Cancer Research), Neha Chopra(Schrodinger (United States)), Karen E. Swales(Institute of Cancer Research), Ines Figueiredo(Institute of Cancer Research), Vasiliki Michalarea(Royal Marsden Hospital)
Cited by 134
Related Papers
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k